Evidence map›Paper›PMID 41157098›Full record

ReviewMolecules (Basel, Switzerland)2025

Hydroxyketone Tyrosinase Inhibitors: Mechanism of Action, Applications and Perspectives in Depigmentation and Melanoma Therapy.

Barbara Bogdańska, Dmytro Khylyuk, Dariusz Matosiuk

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Characterization ofPlants (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Barbara BogdańskaDoctoral School, Medical University of Lublin, 20-093 Lublin, Poland.ORCID 0000-0003-4900-964X
Dmytro KhylyukDepartment of Organic Chemistry, Faculty of Pharmacy, Medical University of Lublin, Chodzki 4A, 20-093 Lublin, Poland.ORCID 0000-0001-9306-7463
Dariusz MatosiukDepartment of Synthesis and Chemical Technology of Pharmaceutical Substances, Faculty of Pharmacy, Medical University of Lublin, Chodzki 4A, 20-093 Lublin, Poland.ORCID 0000-0002-2373-9479

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tyrosinase is a key enzyme in melanogenesis, playing an important role in skin, hair, and eye pigmentation, as well as in the enzymatic browning of fruits and vegetables. Excessive tyrosinase activity leads to hyperpigmentation and other dermatological problems, and it also causes losses in the food industry. For this reason, tyrosinase inhibitors have become the subject of intensive research in medicine, cosmetology, and food technology. Among various inhibitors, compounds containing ketone and hydroxyl groups draw special attention, because they have the ability to chelate copper ions in enzyme's active center or block access to it. This article discusses the possible mechanisms of action, based on molecular modeling of interaction of PDB database retrieved model of enzyme with known natural inhibitors-kojic acid and tropolone, as well as 6-hydroxyimino derivatives of imidazo[1,2-a]imidazole-5-ones. The results suggest that the model of enzyme-ligand interaction can be useful in establishing affinity to tyrosinase of new natural and synthetic inhibitors, which can have broad applications in various fields, particularly in medicine and cosmetology, with promising prospects for further development.

Indexed as

Enzyme InhibitorsMelanomaMonophenol MonooxygenaseAnimalsHumansModels, MolecularPyronesEnzyme Inhibitorskojic acidMonophenol MonooxygenasePyronesdepigmentationhydroxyketonesmelanomamolecular modelingtyrosinase inhibitors

Identifiers

PMID41157098
PMCPMC12566265

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.